APLS Quote, Financials, Valuation and Earnings

Fortress Biotech, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 50.07%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Fortress Biotech, Inc.'s return on equity of -223.06%.

Apellis Pharmaceuticals, Inc. has a consensus price target of $35.00, signalling upside risk potential of 43.57%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 203.67%. Given that Fortress Biotech, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc. has a beta of 0.368, which suggesting that the stock is 63.199% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.031%.

Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Fortress Biotech, Inc. quarterly revenues of $17.6M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 83.00x while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 3.07x versus 1.67x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 10.24%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Apellis Pharmaceuticals, Inc. has a consensus price target of $35.00, signalling upside risk potential of 43.57%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 8.67%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..

Apellis Pharmaceuticals, Inc. has a beta of 0.368, which suggesting that the stock is 63.199% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 83.00x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 3.07x versus 7.26x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Fulcrum Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 69.26%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Fulcrum Therapeutics, Inc.'s return on equity of -31.15%.

Apellis Pharmaceuticals, Inc. has a consensus price target of $35.00, signalling upside risk potential of 43.57%. On the other hand Fulcrum Therapeutics, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 54.72%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc. has a beta of 0.368, which suggesting that the stock is 63.199% less volatile than S&P 500. In comparison Fulcrum Therapeutics, Inc. has a beta of 3.172, suggesting its more volatile than the S&P 500 by 217.163%.

Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fulcrum Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Fulcrum Therapeutics, Inc. quarterly revenues of --. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Fulcrum Therapeutics, Inc.'s net income of -$19.6M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 83.00x while Fulcrum Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 3.07x versus -- for Fulcrum Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of -112.81%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Apellis Pharmaceuticals, Inc. has a consensus price target of $35.00, signalling upside risk potential of 43.57%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $81.85 which suggests that it could grow by 144.33%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc. has a beta of 0.368, which suggesting that the stock is 63.199% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.763%.

Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 83.00x while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 3.07x versus 5.18x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.